W. Al-herz, A. Bousfiha, and J. Casanova, Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency, Front Immunol, vol.5, p.162, 2014.

A. J. Ullmann, M. Akova, and R. Herbrecht, ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT), Clin Microbiol Infect, vol.18, issue.7, pp.53-67, 2012.

B. H. Segal, T. L. Leto, J. I. Gallin, H. L. Malech, and S. M. Holland, Genetic, biochemical, and clinical features of chronic granulomatous disease, vol.79, pp.170-200, 2000.

S. Blumental, R. Mouy, and N. Mahlaoui, Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey, Clin Infect Dis, vol.53, pp.159-69, 2011.

R. S. Weening, P. Kabel, P. Pijman, and D. Roos, Continuous therapy with sulfamethoxazole-trimethoprim in patients with chronic granulomatous disease, J Pediatr, vol.103, pp.127-157, 1983.

D. M. Margolis, D. A. Melnick, D. W. Alling, and J. I. Gallin, Trimethoprimsulfamethoxazole prophylaxis in the management of chronic granulomatous disease, J Infect Dis, vol.162, pp.723-729, 1990.

R. Mouy, A. Fischer, E. Vilmer, R. Seger, and C. Griscelli, Incidence, severity, and prevention of infections in chronic granulomatous disease, J Pediatr, vol.114, pp.555-60, 1989.

J. I. Gallin, D. W. Alling, and H. L. Malech, Itraconazole to prevent fungal infections in chronic granulomatous disease, N Engl J Med, vol.348, pp.2416-2438, 2003.

, A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group, N Engl J Med, vol.324, pp.509-525, 1991.

R. Mouy, R. Seger, and J. P. Bourquin, Interferon gamma for chronic granulomatous disease, N Engl J Med, vol.325, pp.1516-1523, 1991.

J. M. Van-den-berg, E. Van-koppen, and A. Ahlin, Chronic granulomatous disease: the European experience, PLoS One, vol.4, p.5234, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00382226

, Medical Advisory Committee of the Immune Deficiency Foundation

W. T. Shearer, T. A. Fleisher, and R. H. Buckley, Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts, J Allergy Clin Immunol, vol.133, pp.961-967, 2014.

J. Donadieu, O. Fenneteau, B. Beaupain, N. Mahlaoui, and C. B. Chantelot, Congenital neutropenia: diagnosis, molecular bases and patient management, Orphanet J Rare Dis, vol.6, p.26, 2011.

D. C. Dale, M. A. Bonilla, and M. W. Davis, A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia, Blood, vol.81, pp.2496-502, 1993.

S. Ram, L. A. Lewis, and P. A. Rice, Infections of people with complement deficiencies and patients who have undergone splenectomy, Clin Microbiol Rev, vol.23, pp.740-80, 2010.

C. Picard, A. Puel, J. Bustamante, C. Ku, and J. Casanova, Primary immunodeficiencies associated with pneumococcal disease, Curr Opin Allergy Clin Immunol, vol.3, pp.451-460, 2003.

C. G. Whitney, M. M. Farley, and J. Hadler, Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine, N Engl J Med, vol.348, pp.1737-1783, 2003.

T. Vesikari, S. Esposito, and R. Prymula, Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials, Lancet, vol.381, pp.825-860, 2013.

J. M. Langley, L. Dodds, D. Fell, and G. R. Langley, Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study, BMC Infect Dis, vol.10, p.219, 1990.

M. H. Gaston, J. I. Verter, and G. Woods, Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial, N Engl J Med, vol.314, pp.1593-1602, 1986.

A. J. Fried and F. A. Bonilla, Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections, Clin Microbiol Rev, vol.22, pp.396-414, 2009.

E. Halliday, J. Winkelstein, and A. Webster, Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality, J Infect, vol.46, pp.1-8, 2003.

H. M. Chapel, G. P. Spickett, D. Ericson, W. Engl, M. M. Eibl et al., The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy, J Clin Immunol, vol.20, pp.94-100, 2000.

I. Quinti, A. Soresina, and A. Guerra, Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study, J Clin Immunol, vol.31, pp.315-337, 2011.

J. S. Orange, W. J. Grossman, R. J. Navickis, and M. M. Wilkes, Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a metaanalysis of clinical studies, Clin Immunol, vol.137, pp.21-30, 2010.

A. G. Dirienzo, C. Van-der-horst, D. M. Finkelstein, P. Frame, S. A. Bozzette et al., Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection, AIDS Res Hum Retroviruses, vol.18, pp.89-94, 2002.

R. K. Albert, J. Connett, and W. C. Bailey, Azithromycin for prevention of exacerbations of COPD, N Engl J Med, vol.365, pp.689-98, 2011.

H. Chapel and C. Cunningham-rundles, Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions, Br J Haematol, vol.145, pp.709-736, 2009.

M. Malphettes, L. Gérard, and M. Carmagnat, Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect, Clin Infect Dis, vol.49, pp.1329-1367, 2009.

M. Lucas, M. Lee, J. Lortan, E. Lopez-granados, S. Misbah et al., Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years, J Allergy Clin Immunol, vol.125, pp.1354-60, 2010.

S. Goldacker, R. Draeger, and K. Warnatz, Active vaccination in patients with common variable immunodeficiency (CVID), Clin Immunol, vol.124, pp.294-303, 2007.

V. Lougaris, R. Badolato, S. Ferrari, and A. Plebani, Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features, Immunol Rev, vol.203, pp.48-66, 2005.

. Immunocompromised-hosts-?-cid, , p.1469, 2014.

, Institut Pasteur user on, vol.22, 2020.

A. Durandy, P. Revy, K. Imai, and A. Fischer, Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects, Immunol Rev, vol.203, pp.67-79, 2005.

A. Fischer, Severe combined immunodeficiencies (SCID), Clin Exp Immunol, vol.122, pp.143-152, 2000.

R. H. Buckley, Primary cellular immunodeficiencies, J Allergy Clin Immunol, vol.109, pp.747-57, 2002.

J. L. Stephan, V. Vlekova, L. Deist, and F. , Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients, J Pediatr, vol.123, pp.564-72, 1993.

R. H. Buckley, R. I. Schiff, and S. E. Schiff, Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants, J Pediatr, vol.130, pp.378-87, 1997.

S. M. Holland, F. R. Deleo, and H. Z. Elloumi, STAT3 mutations in the hyper-IgE syndrome, N Engl J Med, vol.357, pp.1608-1627, 2007.

A. F. Freeman and S. M. Holland, The hyper-IgE syndromes, Immunol Allergy Clin North Am, vol.28, pp.277-91, 2008.

M. Chandesris, I. Melki, and A. Natividad, Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey, Medicine (Baltimore), vol.91, pp.1-19, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00717018